BusinessPhoto: Mint MarketsPL Capital Rates Sai Lifesciences 'Buy' with ₹1,620 Target
PL Capital has initiated coverage on Sai Lifesciences with a 'Buy' rating and a target price of ₹1,620 per share, indicating a 16% upside from the current ₹1,394. The brokerage highlights Sai Lifesciences' strong position in pharmaceutical outsourcing, a robust commercial pipeline, and capacity expansion through its integrated CRDMO platform. Growth is expected from large pharma clients and late-stage molecule manufacturing.
Mint Markets·



